Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Luke J, Castro, Kyleen E, Xu, Binzhi, Li, Junyi, Dinh, Nguyen B, Thompson, Jordan M, Woytash, Jordan, Kipp, Kevin R, Razorenova, Olga V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037521/
https://www.ncbi.nlm.nih.gov/pubmed/35240916
http://dx.doi.org/10.1080/15384101.2022.2041783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037521/
https://www.ncbi.nlm.nih.gov/pubmed/35240916
http://dx.doi.org/10.1080/15384101.2022.2041783

Ejemplares similares